MRNA

Moderna said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to six countries in the region.

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary. The stock extended its recent rally after climbing to a new annual high on Wednesday.

The semiconductor rotation and memory stock profit taking puts investors in a bind trying to call the top.

At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.